Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions

The majority of lung cancers are non-small-cell lung cancer (NSCLC) having a low survival rate. Recent studies have indicated the involvement of epidermal growth factor receptor (EGFR) oncogene mutations like EGFR exon 20 insertions (EGFRex20ins) mutation among NSCLC patients. The response of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Imran, Mohd, Khan, Shah Alam, Alshammari, Mohammed Kanan, Alreshidi, Meshal Ayedh, Alreshidi, Abeer Abdullah, Alghonaim, Rawan Sulaiman, Alanazi, Fayez Aboud, Alshehri, Sultan, Ghoneim, Mohammed M., Shakeel, Faiyaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698942/
https://www.ncbi.nlm.nih.gov/pubmed/34944754
http://dx.doi.org/10.3390/biomedicines9121938

Ejemplares similares

Ejemplares similares